EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dose–response analysis of valproate, levetiracetam and lamotrigine in idiopathic generalized epilepsy

Amine Abdullah-Roskjær, Joanna Gesche, Guido Rubboli, Christoph P Beier

Epilepsy & Behavior · 2026

DOI: 10.1016/j.yebeh.2026.110940 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsy & Behavior, 2026. Verfasst von Amine Abdullah-Roskjær und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Odense University Hospital, Denmark. Hauptthemen laut MEDLINE: Levetiracetam, Anticonvulsants, Epilepsy, Generalized, Lamotrigine. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jascha Foundation, Odense Universitetshospital, Region Syddanmark.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate dose-response relationships for valproate, levetiracetam, and lamotrigine in adults with idiopathic generalized epilepsy (IGE). METHOD: A retrospective cohort study was conducted including 473 adults (≥16 years) with IGE treated at Odense University Hospital from 2015 to 2021. Patients were stratified into predefined daily dose categories for levetiracetam, lamotrigine, and valproate. The primary outcome was seizure freedom, defined as no seizures in the past 12 months or three times the longest pre-treatment inter-seizure interval. Dose-response was analyzed using chi-square tests and multivariate logistic regression adjusted for age, sex, and IGE subsyndrome. RESULTS: Valproate exhibited a linear dose-response: seizure freedom rates were 47.2% (0-1200 mg/day), 56.4% (1201-2400 mg/day), and 60.0% (>2400 mg/day, p < 0.001). Levetiracetam showed increasing seizure freedom up to 2000 mg/day, with a plateau at higher doses. In contrast, lamotrigine was most effective at moderate doses (201-400 mg/day; 27.7%) with decreasing efficacy at higher doses. Multivariate regression controlling for age, sex, and IGE subsyndrome confirmed these associations. CONCLUSION: Both valproate and levetiracetam show a clear dose-response in IGE. In contrast, increasing lamotrigine doses above 400 mg/day did not confer additional effect on seizures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevetiracetamAnticonvulsantsEpilepsy, GeneralizedLamotrigineValproic AcidHumansFemaleMaleDose-Response Relationship, DrugAdultRetrospective StudiesMiddle AgedYoung AdultAdolescentAgedCohort Studies

Substanzen

LevetiracetamAnticonvulsantsLamotrigineValproic Acid

Autor:innen und Institutionen

  • Department of Neurology, Odense University Hospital, Denmark.
  • Department of Neurology, Odense University Hospital, Denmark; Danish Epilepsy Center, Dianalund, Denmark.
  • Danish Epilepsy Center, Dianalund, Denmark; Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Department of Neurology, Odense University Hospital, Denmark; Department of Clinical Research, University of Southern Denmark, Denmark. Electronic address: cbeier@health.sdu.dk.

Förderung

  • Jascha Foundation
  • Odense Universitetshospital
  • Region Syddanmark
  • Lundbeck Foundation

Zitieren

APA

Abdullah-Roskjær, A., Gesche, J., Rubboli, G., & Beier, C. P. (2026). Dose–response analysis of valproate, levetiracetam and lamotrigine in idiopathic generalized epilepsy. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2026.110940

Vancouver

Abdullah-Roskjær A, Gesche J, Rubboli G, Beier CP. Dose–response analysis of valproate, levetiracetam and lamotrigine in idiopathic generalized epilepsy. Epilepsy & Behavior. 2026. doi:10.1016/j.yebeh.2026.110940

BibTeX
@article{AbdullahRoskjr2026,
  author = {Abdullah-Roskjær, Amine and Gesche, Joanna and Rubboli, Guido and Beier, Christoph P},
  title = {Dose–response analysis of valproate, levetiracetam and lamotrigine in idiopathic generalized epilepsy},
  journal = {Epilepsy & Behavior},
  year = {2026},
  doi = {10.1016/j.yebeh.2026.110940}
}
Kostenlos starten →